Showing results (201-210 of 900) with videos related to
Sort By:
Pageof 90
Leukemia|June 21, 2020
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemiaMansour Alfayez, Ghayas C Issa, Keyur P Patel, et al.American Journal of Hematology|August 5, 2021
Development of TP53 mutations over the course of therapy for acute myeloid leukemiaYasmin Alwash, Joseph D Khoury, Mehrnoosh Tashakori, et al.Cancer|December 7, 2018
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypesPrajwal C Boddu, Tapan M Kadia, Guillermo Garcia-Manero, et al.Blood Cancer Journal|June 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemiaElias Jabbour, Caitlin R Rausch, Hannah Goulart, et al.Lancet (London, England)|August 7, 2018
Acute myeloid leukaemiaNicholas J Short, Michael E Rytting, Jorge E CortesCancer|April 6, 2021
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinibKiyomi Morita, Hagop M Kantarjian, Koji Sasaki, et al.Cancer|March 18, 2021
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approachHagop M Kantarjian, Tapan M Kadia, Courtney D DiNardo, et al.British Journal of Haematology|May 15, 2004
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myelomaMohamad A Hussein, Mansoor Saleh, Farhad Ravandi, et al.Cancer|January 16, 2007
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaAhmed Aribi, Gautam Borthakur, Farhad Ravandi, et al.Expert Review of Anticancer Therapy|December 18, 2009
Decitabine in the treatment of myelodysplastic syndromesFabio P S Santos, Hagop Kantarjian, Guillermo Garcia-Manero, et al.Pageof 90